weiguo2122
☆    

2024-06-26 22:17
(374 d 10:33 ago)

Posting: # 24040
Views: 2,436
 

 BE between one injection vs multiple injection products [Design Issues]

Hi, Dear all,
A product A currently is injected weekly for 4 weeks as one treatment term, we would have a slowly release product A (slow-A), which will be injected monthly. Then we would like to access the BE of A injected 4 time vs slow-A injected 1 time. How is this type of BE between one injection vs multiple injection conducted?

Cmax?

sum of AUCA1-4 vs AUC_slow-A?

Is there any guidance from FDA or EMA.

Any help is greatly appreciated.
weiguo2122
☆    

2024-06-27 17:07
(373 d 15:43 ago)

@ weiguo2122
Posting: # 24044
Views: 1,930
 

 BE between one injection vs multiple injection products

That should not be a BE study? Then what should be considered when we develop product from daily injection to weekly as well as weekly to monthly?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]
UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,676 registered users;
64 visitors (0 registered, 64 guests [including 29 identified bots]).
Forum time: 08:51 CEST (Europe/Vienna)

Many people tend to look at programming styles and languages like religions:
if you belong to one, you cannot belong to others.
But this analogy is another fallacy.    Niklaus Wirth

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5